XBIOTECH INC. (XBIT)
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
Meet the New Chase Sapphire Preferred: Earn More Than Ever, Same $95 Annual Fee
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
AI Data Center Growth Hinges on Solving Both Power Constraints and Community Concerns, Bloom Energy Report Finds
Markel Canada Strengthens Contractors, Trades and Construction Services (CTCS) Sector Leadership With Key Appointments
Celanese and Siegwerk Collaborate to Advance More Sustainable Printing Ink Solutions with Bio-Based Ethyl Acetate
BrightSpire Capital Announces $0.16 Per Share Dividend for Second Quarter 2026
Wells Fargo Named as ICON Preferred Mortgage Lender to Support 3D‑Printed Homes
NexPoint Diversified Real Estate Trust Announces Investor Update Call
Principal Asset Management® Launches Fixed Income ETF Suite